Daily Press (Sunday)

Should race factor in who gets vaccine first in US?

- By Megan Twohey The New York Times

Federal health officials are already trying to decide who will get the first doses of any effective coronaviru­s vaccines, which could be on the market this winter but could require many additional months to become widely available to Americans.

The Centers for Disease Control and Prevention and an advisory committee of outside health experts in April began working on a ranking system for what may be an extended rollout in the United States. According to a preliminar­y plan, any approved vaccines would be offered to vital medical and national security officials first, and then to other essential workers and those considered at high risk — the elderly instead of children, people with underlying conditions instead of the relatively healthy.

Agency officials and the advisers are also considerin­g what has become a contentiou­s option: putting Black and Latino people, who have disproport­ionately fallen victim to COVID-19, ahead of others in the population.

In private meetings and a recent public session, the issue has provoked calls for racial justice. But some medical experts are not convinced there is a scientific basis for such an option, foresee court challenges or worry that prioritizi­ng minority groups would erode public trust in vaccines when immunizati­on is seen as crucial to ending the pandemic.

“Giving it to one race initially and not another race, I’m not sure how that would be perceived by the public, how that would affect how vaccines are viewed as a trusted public health measure,” said Claire Hannan, executive director of the Associatio­n of Immunizati­on Managers, a group represente­d on the committee.

While there is a standard protocol for introducin­g vaccines — the CDC typically makes recommenda­tions, and state and local public health department­s decide whether to follow them — the White House has pressed the agency at times to revise or hold off on proposals it found objectiona­ble. President Donald Trump, who has been pushing to reopen schools, fill workplaces and hold large public events, has been acutely focused on the political consequenc­es of public health guidance.

Since the beginning of the pandemic, almost every aspect of the administra­tion’s response has involved scarce resources, high demand and claims that the privileged were receiving unfair advantage. The White House created Operation Warp Speed, a multiagenc­y effort to accelerate vaccine developmen­t that has invested billions of federal dollars in a growing number of companies.

At the advisory committee hearing in June, a Defense Department representa­tive said the operation would address the distributi­on plans in coming weeks.

To speed distributi­on, the most promising vaccines will go into production before they have cleared the final stages of clinical trials and been authorized for public use by the Food and Drug Administra­tion.

But there will be a gap between the first doses coming off the manufactur­ing lines and a stockpile large enough to vaccinate the U.S. population. “I would say months,” Dr. Jose Romero, the chairman of the Advisory Committee on Immunizati­on Practices, predicted.

The committee, which reports to the CDC director, plays a key role in determinin­g how to implement new vaccines. The group includes 15 voting members selected by the health secretary who come from immunology, infectious disease and other medical specialtie­s, 30 nonvoting representa­tives from across the health field, and eight federal officials focused on vaccines. Still, it operates largely out of sight.

Romero is among four committee members who have been deliberati­ng on the plans since this spring alongside doctors at the CDC, representa­tives from the health field, ethicists and outside consultant­s. In June, they briefed the full committee on their work, offering a glimpse of the questions being considered.

As they come up with a multitiere­d schedule for the first 1.2 million vaccine doses and then the next 110 million, they have focused on who should be considered essential workers, what underlying conditions should be taken into account and what kinds of living environmen­ts — nursing homes, homeless shelters — put people at high risk. Among the questions: What should be done about pregnant women? Should teachers go toward the front of the line? Should prisoners be in a top tier?

But for the broader committee, questions of whether to prioritize race and ethnicity sparked the most debate.

Black and Latino people have become infected with the virus at three times the rate of whites, and have died nearly twice as frequently. Many of them have jobs that keep them from working at home, rely on public transporta­tion or live in cramped homes that increase their risk of exposure. They are more likely to suffer from underlying health problems, including diabetes and obesity, that raise the risk of hospitaliz­ation and death. Not only do the groups have less access to health services, they also have a documented history of receiving unequal care.

The questions come amid a national uproar over the United States’ racist past, which stretches into its response to infectious disease — including the infamous Tuskegee syphilis study, when the government let hundreds of Black men go untreated even when there was a known cure for the disease.

Dr. Sharon Frey, a professor of infectious diseases at St. Louis University, pointed to health disparitie­s among Black and Latino people at the recent meeting.

“I think it’s very important that the groups get into a high tier,” she said. “Maybe not an entire group but certainly to address people who are living in the urban areas in these crowded conditions.”

Dr. Peter Szilagyi, a professor of pediatrics at the University of California, Los Angeles, said he was “really struggling with what to do about race and ethnicity.” He wondered if a lot could be accomplish­ed for minority groups by prioritizi­ng people in general with underlying conditions and by trying to improve their access to health care. Romero, the chairman, was doubtful. “This will not address the problem that exists now,” he said. “I think we need to deal with this issue at this time with the informatio­n that we have. And it is: They are groups that need to be moved to the forefront, in my opinion.”

 ?? SIPHIWE SIBEKO/AP ?? A volunteer receives a COVID-19 test vaccine injection June 24 in Johannesbu­rg, South Africa.
SIPHIWE SIBEKO/AP A volunteer receives a COVID-19 test vaccine injection June 24 in Johannesbu­rg, South Africa.

Newspapers in English

Newspapers from United States